公开(公告)号：US20190201540A1

公开(公告)日：2019-07-04

申请号：US16304020

申请日：2017-05-24

Applicant: Bryce Chackerian ,  Alan Remaley ,  Ingrid Lindquist ,  Ingrid Lindquist ,  STC UNM

Inventor： Bryce Chackerian ,  Alan Ramaley ,  Ingrid Lindquist

IPC: A61K47/64 ,  A61K39/00 ,  A61K39/12 ,  A61K47/69 ,  C07K14/775 ,  A61P3/06 ,  C12N15/85

CPC classification number: A61K47/646 ,  A61K39/0005 ,  A61K39/12 ,  A61K45/06 ,  A61K47/6901 ,  A61K2039/62 ,  A61P3/06 ,  C07K14/775 ,  C12N15/85 ,  C12N2795/18123

Abstract: This disclosure describes immunogens, compositions, and methods for treating dyslipidemia. The immunogen included an ApoC3-derived peptide linked to a bacteriophage virus like particle (VLP) immunogenic carrier. The ApoC3 immunogen can be administered to a subject having, or at risk of having, dyslipidemia. The ApoC3 immunogen may be administered alone or co-administered with an additional dyslipidemia therapeutic agent.

公开(公告)号：US07378274B2

公开(公告)日：2008-05-27

申请号：US09846456

申请日：2001-05-02

Applicant: Marie-Françoise Rosier-Montus ,  Catherine Prades ,  Cendrine Lemoine ,  Laurent Naudin ,  Patrice Denefle ,  Nicolas Duverger ,  Bryan Brewer ,  Alan Remaley ,  Sylvia Santamarina-Fojo

Inventor： Marie-Françoise Rosier-Montus ,  Catherine Prades ,  Cendrine Lemoine ,  Laurent Naudin ,  Patrice Denefle ,  Nicolas Duverger ,  Bryan Brewer ,  Alan Remaley ,  Sylvia Santamarina-Fojo

IPC: C07H21/04 ,  C12N15/00 ,  C12N5/00 ,  C12N1/00

CPC classification number: C07K14/705 ,  A01K2217/05 ,  A61K38/00 ,  G01N2500/10

Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.

Abstract translation: 本发明涉及一种能够调节ABC1基因转录的核酸，该ABC1基因是与胆固醇代谢功能异常有关的病理学的致病基因，诱导诸如动脉粥样硬化的疾病。 本发明还涉及包含编码感兴趣的多肽或核酸的多核苷酸的核苷酸构建体，其在控制下置于ABC1基因的调控核酸上。 本发明还涉及重组载体，转化宿主细胞和非人类转基因哺乳动物，其包含调节ABC1基因或上述核苷酸构建体的转录的核酸，以及用于筛选能够改变活性的分子或物质的方法 ABC1基因的调控核酸。

公开(公告)号：US06846636B1

公开(公告)日：2005-01-25

申请号：US09700455

申请日：1999-05-13

Applicant: William S. Argraves ,  Samar Hammad ,  Steingrimur Stefansson ,  Bryan Brewer ,  Alan Remaley

Inventor： William S. Argraves ,  Samar Hammad ,  Steingrimur Stefansson ,  Bryan Brewer ,  Alan Remaley

IPC: C07K14/705 ,  G01N33/53 ,  C07K14/00 ,  C12Q1/62 ,  G01N33/566 ,  G01N33/92

CPC classification number: C07K14/705

Abstract: The present invention provides an isolated mammalian receptor which specifically binds a high density lipoprotein holoparticle, comprising a subunit of approximately 45-600 kDa molecular weight and one or more subunits selected from the group consisting of a subunit of approximately 40-50 kDa molecular weight, a subunit of approximately 120 kDa molecular weight and a subunit of approximately 400 kDa molecular weight. In addition, the present invention provides a method of screening a substance for the ability to modulate the HDL holoparticle binding and/or internalization activity of the receptor of this invention, comprising: a) contacting the substance with a cell producing a functional HDL receptor; and b) assaying the cell for a modulation of the HDL holoparticle binding and/or internalization activity of the receptor, whereby a modulation of the HDL holoparticle binding and/or internalization activity of the receptor identifies a substance with the ability to modulate the HDL holoparticle binding and/or internalization activity of the ADL receptor.

Abstract translation: 本发明提供了分离的哺乳动物受体，其特异性结合高密度脂蛋白holoparticle，其包含约45-600kDa分子量的亚基和一个或多个选自约40-50kDa分子量亚基的亚单位， 约120kDa分子量的亚基和约400kDa分子量的亚单位。 此外，本发明提供了筛选物质以调节本发明受体的HDL holodarticle结合和/或内化活性的能力的方法，包括：a）使物质与产生功能性HDL受体的细胞接触; 和b）测定细胞以调节受体的HDL holoparticle结合和/或内化活性，由此受体的HDL holodarticle结合和/或内化活性的调节鉴定具有调节HDL holoparticle的能力的物质 ADL受体的结合和/或内化活性。

公开(公告)号：US11633471B2

公开(公告)日：2023-04-25

申请号：US16977648

申请日：2019-03-06

Applicant: UNM Rainforest Innovations ,  The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Bryce Chackerian ,  Alan Remaley ,  Marcelo Amar ,  Alexandra Fowler

Inventor： Bryce Chackerian ,  Alan Remaley ,  Marcelo Amar ,  Alexandra Fowler

IPC: A61K39/385 ,  A61K47/69 ,  A61K39/00 ,  A61K45/06 ,  C12N7/00

Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.